Dosing underway in Sangamo’s early-stage study of gene therapy SB-525 in hemophilia A – Seeking Alpha
|
Dosing underway in Sangamo's early-stage study of gene therapy SB-525 in hemophilia A
Seeking Alpha The first patient has been treated in a Phase 1/2 clinical trial, Alta, assessing Sangamo Therapeutics' (NASDAQ:SGMO) gene therapy candidate SB-525. The open-label dose-ranging study will evaluate the safety and tolerability of SB-525 in 20 adults with … Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 … |
